www.twitter.com/BioTimeBTX We're continuing to create progress towards our objective to end up being the leader in the field of regenerative medicine. We've the right staff inplace to capitalize on the opportunities in the industry, and we will soon be one-step closer to obtaining the top property portfolio in regenerative medicine when our subsidiary Asterias Biotherapeutics, Inc. Completes the purchase of Geron’s stem cell assets by the end of the 3rd quarter this year,” explained Dr. Michael West, BioTime’s Ceo. In addition, we continued to improve capital to fund our efforts to provide adequate capital in order that we can continue our work in this important discipline of medicine.” I and the previous workforce at Geron, including Dr. Tom Okarma who ran Geron for several years, felt a deep sense of obligation to join forces in an attempt to get and reassemble the stem cell possessions of Geron. It hasn’t been simple, but I'm happy to say that by today, the applications are legally reborn as “Asterias Biotherapeutics.” A good regenerative medicine deal has been discovered for the time being about how to retool the process development to make a better product. Main point here, we all now in the contest full-speed to translate this technology to as much essential medical purposes as possible.” Underneath the conditions of the Agreement, Geron has brought to Asterias its base cell intellectual property, multiple lots of OPC1 drug product (hES cell-derived oligodendrocytes) utilized in the world’s initial human clinical trial of hES-derived cells in subacute spinal cord injury, multiple lots of hESC production cell banks – the starting material to manufacture added lots of OPC1 drug product and to create regenerative medicine dendritric cells for cancer immunotherapy, chondrocytes for cartilage and disc restoration, and cardiomyocytes for heart problems. Geron has also brought most of the clinical and regulatory documents pertaining to the OPC1 and VAC1 (autologous dendritic cells) clinical tests, as well as a series of stem-cell-related out-licenses. BioTime's outstanding subsidiaries are OrthoCyte, which has not created any newsworthy events in the 11 months as a result of its acquisition last year, OncoCyte, and LifeMap Sciences These last two are active in the present challenge du jour, the PanC-Dx cancer test. As we will discuss in future articles, the PanC-Dx cancer test has rather lengthy odds of actually generating important revenues. We are curious to find out when the PanC-Dx challenge basically apparently vanishes, as happened with Mobile Cure and its OpRegen system now that PanC-Dx has served its reason for substantially improving BioTime's share-price. Utilizing proprietary technology, we have also produced analysis- and scientific-grade human embryonic stem (hES) cell lines that we market to researchers, scientists, universities, and businesses. Our part ES Cell International (ESI) is promoting six hES cell lines that are one of the better-known and documented lines available today. These lines were designed utilizing current Good Manufacturing Procedures permitting easy move in to the hospital, and they are thoroughly known with documented and widely available genomic sequences These cell lines also have been approved by the National Institutes of Health (NIH) and are contained in the NIH Stem Cell Registry. The ESI hES cell lines can be found for-sale through BioTime. more information
Related Articles -
stem cells, regenerative medicine, biotechnology, biotech stock, Michael D West, BioTime stock,
|
